Physician profile
Jackky Wang
NPI 1093744617
$3,376.71
in general payments reported to CMS, 2019-2025
33 companies · $983 in 2025
The $983 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $136 · 2021: $121 · 2022: $149 · 2023: $544 · 2024: $758 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,284.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $859.04 | 2019-2025 | |
| Lilly USA, LLC | $357.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.36 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $293.39 | 2019-2025 | Spravato, Xarelto |
| Novo Nordisk INC | $279.59 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $255.90 | 2019-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $122.35 | 2019-2024 | |
| Dexcom, INC. | $89.63 | 2022-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.86 | 2019-2025 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $70.96 | 2022-2025 | Zoryve |
| Sunovion Pharmaceuticals INC. | $67.12 | 2019 | |
| Astellas Pharma US INC | $55.61 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $55.03 | 2021 | |
| Exact Sciences Corporation | $45.83 | 2024-2025 | Cologuard Collection Kit |
| Fidia Pharma USA INC. | $43.07 | 2024 | Hyalgan, Triluron, Hymovis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $38.85 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.20 | 2021-2023 | Eliquis |
| Amgen INC. | $32.78 | 2025 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $29.55 | 2023-2025 | Farxiga, Airsupra |
| Corium, LLC | $28.27 | 2023 | Adlarity |
| Takeda Pharmaceuticals U.S.A., INC. | $25.52 | 2019 | |
| Allergan, INC. | $22.90 | 2019 | |
| Genzyme Corporation | $20.10 | 2024 | |
| Abbvie INC. | $19.95 | 2025 | |
| Bioventus LLC | $16.90 | 2025 | Exogen Ultrasound Bone Healing System |
| Vertex Pharmaceuticals Incorporated | $16.38 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.89 | 2022 | |
| Amarin Pharma, INC. | $15.74 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.86 | 2025 | Euflexxa |
| Collegium Pharmaceutical, INC. | $13.47 | 2025 | Xtampza |
| Lundbeck LLC | $13.41 | 2023 | Rexulti |
| Shire North American Group INC | $11.80 | 2019 | |
| Mylan Specialty L.P. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackky Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.